Aktis Oncology (AKTS) insiders disclose major common and preferred holdings
Rhea-AI Filing Summary
Aktis Oncology, Inc. reported initial insider holdings by investment entities associated with MPM Bioimpact. The filing shows indirect beneficial ownership of 341,709 shares of Common Stock and indirect holdings of preferred stock that can convert into Common Stock. These include 1,314,262 shares of Series Seed Redeemable Convertible Preferred Stock, 5,914,197 shares of Series A Redeemable Convertible Preferred Stock, and 1,577,119 shares of Series B Redeemable Convertible Preferred Stock, all held indirectly through funds and entities such as MPM Asset Management LLC and various MPM BioVentures and Oncology funds.
Each share of the Series Seed, Series A and Series B preferred stock is convertible into Common Stock on a 3.8044-for-1 basis, and these preferred shares will convert into Common Stock upon the closing of the company’s initial public offering. The reporting persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Series Seed Redeemable Convertible Preferred Stock | -- | -- | -- |
| holding | Series A Redeemable Convertible Preferred Stock | -- | -- | -- |
| holding | Series B Redeemable Convertible Preferred Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (6)
- F1. The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
- F2. The shares are held by MPM Asset Management LLC, of which Dr. Gadicke is the manager.
- F3. Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 3.8044-for-1 basis. Upon the closing of the Issuer's initial public offering, all shares of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock will convert into shares of Common Stock of the Issuer. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock have no expiration date.
- F4. The shares are held as follows: 556,810 by MPM BioVentures 2018, L.P. ("BV 2018"), 29,593 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)"), 10,988 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"), 119,478 by MPM Oncology Innovations Fund, L.P. ("MPM Oncology") and 597,393 by Oncology Impact Private Investment Fund 2, L.P. ("MPM Oncology Impact"). MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Drs. Evnin and Gadicke are managing directors of BV 2018 LLC and managers of MPM Oncology Innovations Fund GP LLC, which is the general partner of MPM Oncology. Dr. Gadicke is the managing member of MPM Oncology Investments 2 LLC, which is the general partner of MPM Oncology Impact.
- F5. The shares are held as follows: 2,505,648 by BV 2018, 133,170 by BV 2018(B), 49,452 by AM BV2018, 537,654 by MPM Oncology and 2,688,273 by MPM Oncology Impact.
- F6. The shares are held as follows: 668,173 by BV 2018, 35,512 by BV 2018(B), 13,187 by AM BV2018, 143,374 by MPM Oncology and 716,873 by MPM Oncology Impact.
AI-generated analysis. How Rhea-AI works. Not financial advice.
